The global Soliris intravenous market is expected to grow at a significant CAGR during the forecast period (2021-2027). Eculizumab is a medicine that is used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and neuromyelitis optica. It is offered under the trade names Soliris and others. It appears to lower both the breakdown of red blood cells and the requirement for blood transfusions in patients with PNH, but not the risk of mortality. Eculizumab was the first medication to receive FDA clearance in 2007 for each of its applications, and it was based on small trials. It's delivered as an intravenous (IV) infusion in a clinic.

According to the National Organization for Rare Diseases, males and females are thought to be equally affected by PNH. The disease has been discovered globally and has been documented in a variety of racial groupings. People from Southeast Asia and the Far East, who have higher rates of aplastic anaemia, are more likely to develop the disease. Any age group might be affected by the condition. The average age of diagnosis is in the late 30s. Therefore the rising incidences of paroxysmal nocturnal hemoglobinuria are expected to drive the market growth for global Soliris intravenous injection.

As biosimilar applications for Eculizumab were not supposed to be approved by the FDA until March 16, 2019, non-availability of the generic and biosimilars for the drug will drive the market globally. The only generic available of Soliris is Elizaria in Russia. Since the drug is under a multi-year exclusivity period of many national regulators, the biosimilar or generic versions are not likely to enter the market anytime soon. This is a significant factor that will drive the market growth in the forecast period.

In June 2019, Alexion Pharmaceuticals, Inc. stated that the US Food and Drug Administration (FDA) has authorised SOLIRIS for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positivity who have neuromyelitis optica spectrum disease (NMOSD). Anti-AQP4 autoantibodies are found in almost three-quarters of all patients with NMOSD (73%). SOLIRIS was authorised by the FDA after a six-month priority evaluation. NMOSD is an autoimmune illness that targets the central nervous system and is extremely uncommon.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type 

o By Application 

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the world

• Competitive Landscape: Alexion

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Soliris Intravenous Market by Segments

By Type

• Plasma Exchange
• Plasma Infusion

By Application

• PNH
• AHUS
• Neuromyelitis Optica

Global Soliris Intravenous Market by Region